Rocuronium vs. Cisatracurium for Kidney Disease Patients Undergoing Surgery
This study is looking at which combination of medicines used during surgery is safer for people with chronic kidney disease. Specifically, it compares rocuronium with sugammadex versus cisatracurium with neostigmine. These medicines are used to relax your muscles during general anesthesia (when you are put to sleep for surgery) and then to reverse that relaxation. The study wants to see if cisatracurium with neostigmine leads to fewer lung problems after surgery compared to rocuronium with sugammadex. You could be eligible if you are between 18 and 80 years old, have chronic kidney disease, and are having surgery that requires general anesthesia. The study aims to enroll 490 participants.
- Study design
- This interventional study will randomly assign participants into one of two groups to receive either rocuronium with sugammadex or cisatracurium with neostigmine. Both are standard care practices.
- What's involved
- Participants will receive one of the two drug combinations during surgery. They will then be assessed for up to 7 days after surgery for any breathing complications.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be assessed for post-operative pulmonary complications for 7 days after surgery.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease
At a glance
Conditions
NCT07203287
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of Texas Medical Branch
Galveston, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Michael Kinsky, MD · PRINCIPAL_INVESTIGATOR · University of Texas
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Post Operative Pulmonary Complications (PPCs)7 days
PPCs will be scored using a grading scale where 0 = no complication, 1 = mild, 2 = moderate, and 3 = severe complication, with 0 as the minimum score and 3 as the maximum score.